Form D · Other
NV Therapeutics, Inc.
Berkeley, CA · CIK 0002060599
Offering snapshot reported Mar 14, 2025 · SEC filing
- Reported sold
- $3M Offering amount: $7.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 13, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 14, 2025 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-540884
Offer and sale of Series Seed Preferred Stock (and the Common Stock issuable thereunder)
Source: Form D, filed Mar 14, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Dever | Director |
| Kevin Holden | Director, Executive, Promoter |
| Audrey Kozlov | Director |
| Dmitry Kuzmin | Director |
Issuer details
Industry: Other (See others in industry)
Address:
2625 Durant Avenue
Berkeley, CA, 94720
Berkeley, CA, 94720